EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Revaccination Response and Lack of Hepatitis B Reactivation After HCT for Sickle Cell Disease

Henna Butt iD, Neal Jeffries, Triscia Martin, Valeria De Giorgi, Alison Zamora, John F Tisdale, Matthew M Hsieh iD

Transplant Infectious Disease · 2025

DOI: 10.1111/tid.70097 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplant Infectious Disease, 2025. Verfasst von Henna Butt und 6 weiteren Autor:innen. Beteiligte Einrichtung: Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Virus Activation, Hepatitis B, Hepatitis B virus. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Intramural NIH HHS, NHLBI NIH HHS, National Heart, Lung, and Blood Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sickle cell disease (SCD) can be cured by hematopoietic cell transplantation (HCT), but patients face increased risk of hepatitis B virus (HBV) reactivation due to immunosuppression. Understanding hepatitis B surface antibody (anti‐HBs) kinetics is essential for optimizing HBV revaccination and posttransplant care.

Methods

This post hoc analysis examined HBV immunity, reactivation, and revaccination response in 71 SCD patients who underwent HCT at the National Heart, Lung, and Blood Institute (2008–2021) using alemtuzumab and low‐dose total body irradiation.

Results

At baseline, 55% showed HBV immunity (anti‐HBs ≥ 12 mIU/mL). Most patients responded to revaccination regardless of baseline immunity. Post‐HCT revaccination was given to 93%, with 89% completing full series (Heplisav‐B or Engerix‐B). Vaccinated patients had a 67.5% chance of increased anti‐HBs titers between Years 1 and 2, though no significant difference was seen compared to unvaccinated patients ( p = 0.12). No HBV reactivation occurred; two patients with baseline HBcAb and HBsAg positivity showed decreasing HBV DNA levels.

Conclusions

Results indicate that HBV immunity can decline post‐HCT, but most patients remain immune, and revaccination is effective. However, some non‐responders—especially those treated with IVIG, rituximab, or prolonged immunosuppression—need further study. Prospective research is needed to optimize revaccination timing and immune monitoring in this high‐risk group. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Sickle CellVirus ActivationHepatitis BHepatitis B virusHematopoietic Stem Cell TransplantationImmunization, SecondaryHepatitis B VaccinesHumansMaleFemaleAdultHepatitis B AntibodiesYoung AdultMiddle AgedHepatitis B Surface AntigensAdolescentAlemtuzumabImmunosuppressive Agents

Stichwörter der Autor:innen

HCThepatitis Breactivationsickle cell diseasevaccination

Substanzen

Hepatitis B AntibodiesHepatitis B VaccinesHepatitis B Surface AntigensAlemtuzumabImmunosuppressive Agents

Autor:innen und Institutionen

  • Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Center for Cancer and Blood Disorders, Children's National Hospital, Washington, DC, USA.
  • Office of Biostatistics Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
  • Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.

ORCID-Profile: Henna Butt, Matthew M Hsieh

Förderung

  • Intramural NIH HHS
  • NHLBI NIH HHS
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Butt, H., Jeffries, N., Martin, T., De Giorgi, V., Zamora, A., Tisdale, J. F., & Hsieh, M. M. (2025). Revaccination Response and Lack of Hepatitis B Reactivation After HCT for Sickle Cell Disease. Transplant Infectious Disease. https://doi.org/10.1111/tid.70097

Vancouver

Butt H, Jeffries N, Martin T, De Giorgi V, Zamora A, Tisdale JF, et al. Revaccination Response and Lack of Hepatitis B Reactivation After HCT for Sickle Cell Disease. Transplant Infectious Disease. 2025. doi:10.1111/tid.70097

BibTeX
@article{Butt2025,
  author = {Butt, Henna and Jeffries, Neal and Martin, Triscia and De Giorgi, Valeria and Zamora, Alison and Tisdale, John F and Hsieh, Matthew M},
  title = {Revaccination Response and Lack of Hepatitis B Reactivation After HCT for Sickle Cell Disease},
  journal = {Transplant Infectious Disease},
  year = {2025},
  doi = {10.1111/tid.70097}
}
Kostenlos starten →